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Abstract
SHH-activated medulloblastomas (SHH-MB) account for 25–30% of all
medulloblastomas (MB) and occur with a bimodal age distribution, encom-
passing many infant and adult, but fewer childhood cases. Different age
groups are characterized by distinct survival outcomes and age-specific alter-
ations of regulatory pathways. Here, we review SHH-specific genetic aberra-
tions and signaling pathways. Over 95% of SHH-MBs contain at least one
driver event – the activating mutations frequently affect sonic hedgehog
signaling (PTCH1, SMO, SUFU), genome maintenance (TP53), and chromatin
modulation (KMT2D, KMT2C, HAT complexes), while genes responsible for
transcriptional regulation (MYCN) are recurrently amplified. SHH-MBs have
the highest prevalence of damaging germline mutations among all MBs.
TP53-mutant MBs are enriched among older children and have the worst
prognosis among all SHH-MBs. Numerous genetic aberrations, including
mutations of TERT, DDX3X, and the PI3K/AKT/mTOR pathway are almost
exclusive to adult patients. We elaborate on the newest development within
the evolution of molecular subclassification, and compare proposed risk cate-
gories across emerging classification systems. We discuss discoveries based on
preclinical models and elaborate on the applicability of potential new thera-
pies, including BET bromodomain inhibitors, statins, inhibitors of SMO,
AURK, PLK, cMET, targeting stem-like cells, and emerging immunotherapeu-
tic strategies. An enormous amount of data on the genetic background of
SHH-MB have accumulated, nevertheless, subgroup affiliation does not pro-
vide reliable prediction about response to therapy. Emerging subtypes within
SHH-MB offer more layered risk stratifications. Rational clinical trial designs
with the incorporation of available molecular knowledge are inevitable.
Improved collaboration across the scientific community will be imperative for
therapeutic breakthroughs.
Introduction
Medulloblastoma (MB) is the most common pediatric
brain malignancy, accounting for approximately 20% of
childhood brain cancers and 10% of all childhood cancer
deaths. Incidence culminates among children younger
than 10 years of age, with about half of cases arising
before the age of 5.1,2 Up to 40% of patients are diag-
nosed with metastatic disease,3 with a grim outlook for
survival.4 More than one-third of patients die within
5 years after diagnosis, and survivors face treatment-
related long-term adverse effects.5
MB treatment strategy involves maximal safe resection
followed by craniospinal irradiation and cytotoxic
chemotherapy, with specific type and intensity for high- or
standard/average-risk disease. Average-risk patients are
over 3 years of age with total or near-total resection and no
disease dissemination, while patients with suboptimal
tumor resection, metastasis, and/or large cell/anaplastic
(LCA) histology are treated for high-risk disease.6 Infants
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under 3 years of age require delayed irradiation and are
preferably treated by multiagent chemotherapy, with better
results after gross total resection with the absence of dis-
semination compared to patients with residual or meta-
static disease.7–9 Continuing advances in neuroimaging,
neurosurgical techniques, radiation therapy, and combined
chemotherapy have increased 5-year survival rates to 70–
80%,1,5 although individual responses to treatment vary
considerably and survival rates have reached a plateau.10
The highly toxic and invasive multimodal therapies fre-
quently induce debilitating adverse effects on the long
term.11 Evidently, interventions should be spared in
patients likely to be cured and maximized in those with
aggressive disease.
The molecular era lead to exciting transformations in
patient stratifications with consequences for therapeutic
approaches. Based on molecular alterations, four subgroups
became widely accepted: sonic hedgehog-activated (SHH-
MB), wingless-activated (WNT-MB), Group 3, and Group
4 MBs, each characterized by distinct patterns of somatic
mutations, copy number alterations, transcriptional pro-
files, and clinical outcomes.12 WNT- and SHH-activated
MBs have abnormal activation of the WNT and SHH path-
ways, respectively, while no dominant signaling pathway
alterations were identified in Group 3 and Group 4 MBs
and appear as non-WNT/non-SHH in the revised WHO
classification.13 Subgroup assignment is highly prognostic,
with markedly different survival rates.14 The 5-year overall
survival is as high as 95% in WNT-activated MBs. Group 3
patients face the worst 5-year overall survival (45–60%),
especially low among infants. Group 4 and SHH-MBs are
characterized by an intermediate (75–80%) 5-year overall
survival that also depends on disease dissemination, histol-
ogy, and genetic aberrations, such as mutations and onco-
gene amplifications.15–18 Within each primary MBs,
additional subtypes are emerging with distinct biology and
clinical outcomes,18–20 providing a constructive approach
for therapy optimization.14 Here, we provide a comprehen-
sive overview of SHH-MBs with special focus on emerging
prognostication schemes and novel therapeutic approaches.
Clinical Attributes
SHH-MBs account for ~30% of all MBs and occur in a
bimodal age distribution encompassing the majority of
infant and adult, but relatively fewer childhood
cases15,21,22 (Fig. 1A). Pediatric and adult tumors are
molecularly and clinically distinct.12,23 Approximately
21% of SHH-MBs are enriched with TP53-mutations,
delineating a distinct subcategory – “SHH-activated
TP53-wild-type” is more frequent among adults and
young children and confers a good prognosis with an
81% 5-year overall survival (OS). In contrast, the “SHH-
activated TP53-mutant” subtype occurs typically among
older children between ages 5 and 18 and is associated
with a dismal prognosis, including a 41% 5-year OS. In
children older than 5 years, tumors with TP53-mutations
account for two-third of deaths.24
The majority of SHH-MBs are nodular/desmoplastic but
can also have a classic or LCA histology, the latter especially
frequent among children.25,26 The nodular-desmoplastic
subtype predicts increased survival in infants, and in this
young group of patients, radiation therapy may be success-
fully abolished.27–29 Radiation-sparing treatments involve
systemic chemotherapy with intraventricular therapy (HIT-
SKK’92 protocol),7 or high-dose chemotherapy with stem
cell rescue (CCG-99703 protocol).30 Sequential high-dose
chemotherapy following the CCG-99703 protocol resulted
in excellent outcome for SHH-MB patients with classical
histology.31 Nevertheless, conventional chemotherapy,
excluding intraventricular methotrexate, is not feasible as
The Children’s Oncology Group clinical trial (ACNS1221)
for nonmetastatic infants under 4 years of age with nodu-
lar-desmoplastic MB was closed prematurely due to an
excessive number of relapses.32
Molecular Biology
SHH-MBs frequently arise in the cerebellar hemisphere
from cerebellar granule neuron precursors (CGNPs) or
the cochlear nuclei of the brainstem.33 Constitutive SHH-
signaling leads to overproliferation,34–36 therefore SHH
expressed during early postnatal development from Purk-
inje neurons promotes the rapid expansion of CGNPs in
the external granule layer differentiating as granulate neu-
rons migrate into the internal granule layer.
Distinct regulatory processes are altered in different age
groups. Developmental processes and DNA/histone methy-
lation include the most frequently disturbed pathways in
infants, while chromatin organization and transcription reg-
ulation are most heavily involved in adults.26 Despite the age
group-specific molecular features, SHH tumors share com-
mon traits, such as high expression of SHH-signaling target
genes (e.g., Gli family of transcription factors) or CGNP
specification genes (e.g., ATOH1) and relatively low expres-
sion levels of neuronal differentiation genes.26,37–39
Genetic predispositions
SHH-MBs have the highest, 14–20% prevalence of
destructive germline mutations among all MBs, although
less than half are projected based on family history and
medical records. Genetic predispositions influence both
progression-free and overall survival.40 Gorlin syndrome
is associated with mutations affecting PTCH1 and SUFU
genes of the SHH pathway, and Li–Fraumeni syndrome is
ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 991
O. Menyhart & B. Gy}orffy Molecular Drivers of SHH-Medulloblastomas
linked to TP53-mutations predisposing carriers to multi-
ple familial cancers.41 Germline PTCH1 and SUFU muta-
tions are more common among infants with a median
age of 2.0 years and are present in 21% of all infant
SHH-MBs. Hereditary TP53-mutations are most frequent
among children (median age of 9.8 years), present in
~21% of all SHH-MBs patients aged 5–16, and are cou-
pled with a low, 27% 5-year survival.40 Li–Fraumeni syn-
drome-related SHH-MBs are associated with an increased
incidence of chromothripsis, a massive genomic rear-
rangement during a single catastrophic event, resulting in
gene fusions and/or highly amplified copy number states
of recognized oncogenes.40 These findings suggest that
TP53-mutations predispose cells to catastrophic DNA
rearrangements or facilitate cell survival after such
events.42 Accordingly, an outstandingly high mutational
rate characterizes Li–Fraumeni syndrome-associated
SHH-MBs.37 Rare heterozygous germline mutations in
BRCA2 and PALB2 genes were also identified among
SHH-MB patients, coupled with homologous recombina-
tion repair deficiency-like mutation spectrum.40
Because of TP530s crucial role in DNA repair, genome
maintenance, and cell death, radiation therapy may accel-
erate tumor growth, which is particularly important for
patients with Li–Fraumeni syndrome.43 Radiation also
increases the likelihood of secondary malignancies, such
as basal cell carcinomas and other tumors of the skin in
patients with Gorlin syndrome (germline PTCH1 muta-
tion).44 Genetic counseling is recommended for families
in case of TP53-mutations. Additionally, genetic testing is
recommended for germline PTCH1 and SUFU mutations
for children with MB, in children <3 years old, or those
whose tumors show nodular or desmoplastic histologic
features and/or somatic changes in the SHH pathway.45
Copy number variations
Losses of 9q, 10q, and 17p, frequently co-occurring with
TP53-mutations, are the most frequent large-scale chro-
mosomal aberrations in SHH-MB. Focal somatic copy
number aberrations (SCNA) include MDM4 and PPM1D
amplifications and focal deletions of TP53, all involved in
Figure 1. Age-specific distribution of childhood medulloblastomas. (A) Infants, children, and adults are represented differently within each
medulloblastoma subgroup. (B) Dominant mutations across three different age groups in SHH-activated medulloblastomas (SHH-MB). (C)
Schematic representation of major mechanisms most frequently affected by somatic alterations contributing to SHH-MB development.
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TP53-signaling; amplification of GLI2 and deletion of
PTCH1, exclusive for SHH tumors; and amplifications of
MYCN and CCND2. Some SCNAs (including IGF1R,
PIK3C2G, PIK2C2B, KIT, MDM4, PDGFRA, and deletion
of PTEN) are potentially targetable with already available
small molecule inhibitors.38
Mutations
Over 95% of SHH-MBs contain at least one driver event.
However, the types of mutations are highly variable.22,26
Activating mutations almost permanently involve the
SHH-signaling pathway,26 but alterations beyond canoni-
cal SHH-signaling, such as mutations of the IDH1 gene
with epigenetic regulatory function, have also been
recently described.22
The most frequently mutated genes include PTCH1
(~43%), SUFU (~10%), and SMO (~9%), and the pres-
ence of these activating mutations is mutually exclusive
and age group specific22,26,37,39 (Fig. 1B). In a significant
proportion of patients, where PTCH1, SMO, and SUFU
mutations are absent, alternative mechanisms are respon-
sible for SHH-pathway activation.46 PTCH1 mutations
are roughly equally numerous in adults, children, and
infants, while SMO mutations are highly enriched in
adults and SUFU mutations in infants (0–4 years), with
both mutations barely present in children.26 Infants har-
boring germline PTCH1 mutations are diagnosed with
Gorlin syndrome (nevoid basal cell carcinoma).41
SHH-MBs enriched with TP53-mutations (~20%) are
coupled with the highest overall mutational rate of all
MBs. Chromosome 17p loss is common in TP53-mutant
cases.26 Interestingly, WNT-MBs are also enriched with
TP53-mutations, with the second highest mutation rate,
but without the survival disadvantage observed in SHH-
MBs.37 In children, TP53-mutations are mutually exclu-
sive with PTCH1 mutations, but frequently co-occur with
GLI2 and MYCN amplifications, which are essential regu-
lators of transcription22 (Fig. 1B): for example, GLI2 is
the main transcription effector of SHH-signaling in gran-
ule cell precursors.47
Chromatin modulation is frequently affected in SHH-
MBs (Fig. 1C). KMT2D and KMT2C methyltransferase
mutations occur with relatively high frequency within
both pediatric and adult samples.22 Mutations deregulat-
ing histone-acetyltransferase (HAT) complexes involving
genes such as CREBBP, KAT6B, EP300, BRPF1, and
KANSL1 are present in approximately 19% of all SHH-
MB patients.22 Frequently mutated genes also include the
nuclear receptor corepressor complex encoding BCOR,
GPS2, LDB1, GABRG1, and NCOR2.39,48
Mutations of various genes are almost exclusively speci-
fic to the adult subgroup, including alterations in BRPF1/
3 associated with SMO mutations or CREBBP and
KDM3B in PTCH1-mutated tumors.26 Fifty-four percent
of adults and 7% of pediatric samples carry DDX3X
mutations affecting RNA metabolism.26 Telomerase
reverse transcriptase (TERT) promoter mutations that
drive telomerase activity occur with high frequency in
adult SHH-MBs (83% of older patients),49 including the
most-frequent C228T and the less-frequent C250T vari-
ants.26 TERT-mutant SHH tumors carry very few previ-
ously described SCNAs and are mostly mutually exclusive
with 10q loss, possibly underlying the comparatively
favorable prognosis.49 Recurrent mutations of the PI3K/
AKT/mTOR pathway involving PIK3CA, PTEN, and
PIK3C2G mutations also occur mainly in adult patients,
with a surprisingly high frequency: pathway activation
based on p-AKT and p-S6 positivity assessed by IHC was
identified in about 30% of adult SHH patients, with a
strong association with poor outcome.26 We summarize
the most common SHH-MB-specific genetic alterations in
Table S1.
High expression of genes often cannot be traced back
to specific mutations or chromosome aberrations, instead,
might be regulated by epigenetic mechanisms, as methyla-
tion events are more common compared to sequence
mutations. For example, high expression of cMET in
SHH-MBs is not linked to recurrent mutations or ampli-
fications, but is among the most frequently hypo- or
hypermethylated genes in MBs,50 also associated with
prognostic significance.51
Molecular classification
According to the consensus of the International Medul-
loblastoma Working Group, two of four requirements
are suggested to be met for verified SHH activation: (1)
GAB1 immunoreactivity, (2) SHH-signaling-specific
mutation, (3) methylation profiling, or (4) gene expres-
sion profiling consistent with SHH activation either
based on genome-wide arrays or focused gene expression
panels.38,52 Combined immunoreactivity for GAB1,
YAP1, and filamin A distinguishes WNT- and SHH-MBs
from Group 3 and 4 MBs, but GAB1 immunoreactivity
characterizes only SHH-activated tumors.25 The Nano-
String 22 gene signature array determines SHH-pathway
activation based on the differential expression of five
genes (PDLIM3, EYA1, HHIP, ATOH1, and SFRP1) opti-
mized for FFPE samples.38 A second diagnostic multi-
gene signature utilizes the expression of eight genes
(BCHE, GLI1, ITIH2, MICAL1, PDLIM3, PTCH2,
RAB33A, and SFRP1) for SHH-subgroup identification.53
Another unique five-gene signature (GLI1, SPHK1,
SHROOM2, PDLIM3, and OTX2) identifies SHH-MBs
even in the absence of SHH-pathway mutations.54 The
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signature developed by Shou et al. detects all SHH-MBs,
but unable to predict the response to SMO inhibitors26
(Table 1).
Subtypes of SHH-Activated MBs
Based on the presence of metastatic dissemination, TP53-
mutation, and MYCN amplification, the proposed
consensus stratifies SHH-MBs into three risk categories.
Standard risk tumors are nonmetastatic and harbor wild-
type TP53 and no MYCN amplification. Metastatic and/
or MYCN-amplified tumors belong to the high-risk cate-
gory, while very-high-risk tumors contain either somatic
or germline TP53-mutations55 (Fig. 2). Amplification of
MYCN is generally restricted to SHH and Group 4
patients but only associates with poor prognosis in SHH-
MBs and is frequently accompanied by TP53-muta-
tions.14,15,26,56
Additional prognostic biomarkers, such as GLI2 ampli-
fication and LCA histology, strongly affect outcomes in
pediatric samples, but are extremely unusual in adult
tumors.15,26 A large-scale cytogenetic study analyzing
biomarkers in a subgroup-specific manner identified GLI2
amplification, 14q loss, and leptomeningeal dissemination,
but not anaplastic histology, as key biomarkers differenti-
ating clinically high- and low-risk SHH-MBs.14
Integration of methylation- and gene expression-based
data suggests four subtypes: two in infants and one each
in children and adults. SHH a appears primarily in chil-
dren aged 3–16 years, has the worst prognosis of all
SHH-MBs, harbors TP53-mutations, MYCN and GLI2
amplifications, 9q loss, 10q loss, 17p loss, and YAP1
amplifications. TP53- mutations are highly prognostic
only within this subtype. SHH c is present among
infants and is enriched for MBEN histology, representing
a low-risk group potentially suitable for therapy de-esca-
lation. SHH b is also present in infants with high rates
of metastasis and associates with focal PTEN deletions
with worse survival compared to SHH c. SHH d is
mainly present in adults and is associated with TERT
promoter mutations and a favorable prognosis19 (Fig. 2).
A methylomic profile-based analysis divided SHH-acti-
vated childhood MBs into infant and children subtypes
with a cutoff at 4.3 years of age. In children, the pres-
ence of MYCN amplification, LCA pathology, metastasis,
and incomplete resection separated very-high-risk disease
from tumors with a favorable outcome20 (Fig. 2). Two
methylation subtypes were identified in infants with
markedly different molecular alterations and prognosis
in another study: 5-year progression-free survival was
27.8% for the iSHH-I-subtype that harbored SUFU
alterations and chromosome (chr) 2 gains versus 75.4%
Table 1. Identifying subgroup affiliation in childhood medulloblastomas.
WNT SHH Group 3 Group 4 Source Comments Ref.
IHC Nuclear
b-catenin
GAB1 FFPE Least robust: nuclear
b-catenin present
in other subgroups
25
DKK1 SFRP1 NPR3 KCNA1 FFPE 12
Gene
expression
WIF1, DKK2,
TNC, CCDC46,
PYGL
BCHE, GLI1,
ITIH2, MICAL1,
PDLIM3, PTCH2,
RAB33A, SFRP1
n/a n/a Frozen 13-gene multiplex
mRNA expression
assay
53
n/a GLI1, SPHK1,
SHROOM2,
PDLIM3, OTX2
n/a n/a Fresh frozen
and FFPE
54
WIF1, DKK2,
TNC, GAD1,
EMX2
PDLIM3, EYA1,
HHIP, ATOH1,
SFRP1
IMPG2, GABRA5,
EGFL11, NRL,
MAB21L2, NPR3
KCNA1, EOMES,
KHDRBS2,
RBM24, UNC5D,
OAS1
FFPE 38
Mutation CTNNB1
exon 3
52
Structural
aberrations
Chromosome 6
monosomy (FISH
or DNA copy
number array)
52
Methylation Illumina Infinium HumanMethylation 450 BeadChip array Fresh frozen
and FFPE
Also for copy
number profiling
121
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for the iSHH-II-subtype characterized by SMO muta-
tions and chr9q deletions. Patients in the latter subtype
profited from a radiation-free therapy, supporting the
validity of a molecularly driven treatment approach.57
However, inspecting subtype-specific biomarkers reveals
that iSHH-I and iSHH-II likely correspond to the
already described SHH b and SHH c subtypes. Addi-
tional discrepancy across subclassifications stems from
diverse patient populations (only children in20) utilized
data types, and clustering methods. Prospective clinical
trials are in great demand to identify biomarkers suitable
for effective patient stratification.
Proteomics reveal novel stratifications and
translational opportunities
Genomic studies provide invaluable insight into differences
in cancer biology and outcome across MB subgroups.
Nevertheless, translation of the proposed findings to sub-
group-specific therapies remains difficult. Recent proteomic
analyses recapitulated genomic subgrouping, what is more
uncovered posttranscriptional MB heterogeneity not evident
in the genome or the transcriptome.58,59 Since proteomics are
more representative of cellular biology, the approach is well
suited to identify functionally relevant therapeutic targets.
Figure 2. Risk stratification of SHH-activated medulloblastomas including prognostic biomarker candidates across all age groups as defined by
Ramaswamy et al. (2016) (A), Schwalbe et al. (2017) (B) and Cavalli et al. (2017) (C).
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Heterogeneous transcriptional patterns from untreated
SHH, Group 3, and Group 4 MB samples converged only
on two distinct protein-signaling profiles that partially
overlap with molecular subgroups. The profile with
MYC-like signaling encompasses all of SHH-activated and
the majority of Group 3 samples, and is associated with a
rapid death postrecurrence. The rest of Group 3 and the
bulk of Group 4 tumors show enrichment of DNA dam-
age/apoptosis/neuronal signaling.60 Protein profiling
uncovered putative targets for MBs with MYC-like pro-
file, including the inhibition of cell cycle progression and
protein synthesis.60
Protein analysis resulted in an alternative subdivision
of SHH-MBs compared to the age-based split according
to expression- and methylation-based studies.19,20 The
majority of adult samples clustered in the SHHa, while
pediatric samples were split between SHHa and SHHb
subtypes. SHHa signatures contained elevated SOX2, a
regulator of neural progenitors, and mutations of PTCH1,
TERT, and PRKAR1A consistent with canonical SHH-
pathway activation. Proteins in SHHb presented upregula-
tion of calcium, glutamate, and RAS-signaling pathways
and elevated CD47,58 more characteristic to Group 4 than
to SHH-MBs.19 CD47 is a membrane protein that blocks
macrophages from destroying tumor cells,61 and the anti-
CD47 antibody, Hu5F9-G4, demonstrated therapeutic
efficacy in PDX models of Group 3 MBs.62 Hence, focus-
ing at posttranscriptional alterations reveals functionally
relevant novel mechanisms of tumorigenesis with transla-
tional potential. An integrative approach incorporating
data from various “omics” – including protein profiling –
would yield a more complete understanding of cancer
biology, therefore collaborative initiatives facilitating data
sharing are much desired.
Preclinical Models of SHH-MB Reveal
the Mechanisms of Tumorigenesis
Preclinical models provide invaluable tools to study bio-
logical mechanisms underlying MB development and for
evaluating new therapies. Several SHH cell lines have been
established, such as DAOY, UW228, UW426, ONS-76,
with confirmed subgroup identity based on transcrip-
tional profiling.63 Out of the four SHH-MB cell lines, two
are TP53-mutant, DAOY and UW228, reflecting that
more aggressive subtypes are either easier to grow in cul-
tures or more aggressive cells are selected and enriched
in vitro.63
Cell cultures and culture-derived allografts do not
inevitably replicate the phenotypes of the original disease.
Compared to allografts derived from original tumors with
activated SHH-signaling, dependence on SHH-pathway
activation is rapidly lost in cultured tumor cells and
would not be restored when these cells are transplanted
back to nude mice.64 The tumor microenvironment, par-
ticularly tumor-associated astrocytes are starting to
emerge as key components promoting SHH-pathway acti-
vation in vivo.65 Altered in vitro signaling activity has
therapeutic consequences, therefore preclinical models
should be tested for how well they represent the original
disease. Transplantation cancer models utilizing direct
allografts maintain the genetic and histological profiles of
original tumors, presumably better modeling patient
responses to rational therapies.64
Several preclinical mouse models of MB recapitulate
the development of SHH-activated tumors, essentially
through modeling SHH-pathway dysregulation. SHH-
MBs arise from granule cells, yet they also develop in
mice from granule neuron precursors of the cochlear
nuclei.33 Approximately 10–20% of mice with a single-
allele knockout for the Ptch1 gene (Ptch1+/), a negative
inhibitor of the Smo pathway (Fig. 3), develop cerebellar
MBs.66 However the majority of CGNPs with Ptch1 loss
will eventually differentiate into mature neurons,67 and
the relatively low proportion of developing tumors indi-
cates that, besides mutational activation of the SHH path-
way, additional events are necessary for MB formation.
For example, external beam irradiation considerably
increases the tumor incidence rate (~80%).68,69 Following
this first attempt, various models emerged that crossed
Ptch1+/ with other aberrations, including disruption of
DNA repair (DNA ligase IV loss) or cell cycle regulation
(KIP1, INK4C, or INK4D inactivation) in conjunction
with TP53 dysfunction.70–74 Nevertheless, simultaneous
mutations in these pathways are rare in human SHH-
MBs. Constitutive activation of Smoothened (SmoA1) in
mouse CGNPs resulted in highly penetrant tumors with
leptomeningeal metastasis with 48% incidence rates, along
with increased expression of both Sonic hedgehog (Gli1,
NMyc) and Notch (Notch2 and Hes5) target genes.75,76
Mouse models of MB utilizing the Sleeping Beauty
(SB) transposon system provide excellent tools to discern
driver events of tumorigenesis.77 An unbiased SB trans-
poson-based in vivo screen confirmed that a single-allele
loss of MyoD accelerated SHH-MB formation, supporting
the role of MyoD as a novel tumor suppressor in SHH-
MBs.78 A subsequent SB transposon-mediated insertional
mutagenesis screen in single-allele Ptch1-knockout mice
identified transcription factor Nfia as a driver of SHH-
activated MB development, as reduced Nfia conjoined
with SHH-signaling perturbations.79 In the Ptch1+/- tu-
mor model, whole-body SB mutagenesis activated a gene
network of neuronal transcription factors associated with
increased proliferation and decreased differentiation.
Activity of this network was mostly driven by Pten and
Mytil expression and associated with metastatic disease
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Figure 3. Sonic hedgehog signaling is crucial during normal development of cerebellum, and its dysregulation leads to medulloblastoma
development. Mutations of PTCH1, SMO, and SUFU, or amplification of GLI2 contribute to downstream activation of Hedgehog signaling targets.
Several small molecule inhibitors of SMO, such as sonidegib (LDE-225) or vismodegib (GDC-0449), are being investigated as potential targeted
therapies in clinical trials. Mutations downstream of SMO render such inhibitors ineffective. Itraconazole has the ability to inhibit SMO activation
including some SMO mutations that confer resistance to SMO inhibitors, and arsenic trioxide inhibits GLI2 ciliary accumulation.
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and poor survival outcome in human subjects, especially
in SHH-MBs. Network mutations converged on and
increased the Igf2 expression critical for CGNP prolifera-
tion and tumor formation.80
Activation of SHH releases inhibition of Smo by the
transmembrane receptor Ptch1 to activate Gli1/2 tran-
scription activators (GLIA), Gli3, a transcriptional repres-
sor, and downstream mitogenic genes such as Ccnd1 and
Mycn (Fig. 3). In mice, Gli1 functions as an oncogene
during MB development: inactivation of both Gli1 alleles
significantly reduces the incidence of spontaneous MB in
Ptch1+/ mice.81 Hdac-mediated deacetylation of Gli1 via
Hdac1 enzyme promotes transcriptional activation and
enhances SHH-signaling. Members of the Kcash (Kctd
containing, Cullin3 adaptor, suppressor of Hedgehog)
gene family, coding for potassium channel tetramerization
domains, are negative regulators of Hdac1 activity by pro-
moting its ubiquitination, resulting in Gli1 acetylation.
Kcash-s are downregulated in human primary MBs, and
their overexpression leads to growth suppression of MB
cell lines. Kcash-s may represent a novel endogenous
agent capable of restraining SHH-pathway activation.82
Aggressive MBs associated with poor prognosis express
high levels of ATOH1, a critical transcriptional factor
required for the differentiation of cerebellar granular cells
during normal brain development. ATOH1 is usually
absent after the first year of life.83 Deletion of Atoh1 pre-
vents cerebellar neoplasia development in mice.84 In the
Nd2:SmoA1 mouse MB model, Atoh1 protein reduction
markedly decreases MB incidence and increases survival.85
Atoh1 has a central role in the regulation of Gli2, a main
transcriptional effector with an important role in modu-
lating proliferation.84 Jak2-mediated phosphorylation
increases Atoh1 transcriptional activity, thus inhibiting
Jak2-mediated tyrosine phosphorylation may provide a
new mechanism to regulate MB formation.85
Low expression of GNAS has been strongly associated
with decreased overall survival and appears as a potent
tumor suppressor gene in SHH-MBs.86 GNAS encodes
the heterotrimeric Gs protein alpha-subunit (Gsa) and
contributes to signal transduction from the extracellular
environment and controls motility, cell growth, and sur-
vival.87 Gnas-knockout mice develop MB resembling
human tumors in the cerebellum, associated with the
upregulation of SHH-pathway components, such as Gli1,
Gli2, Ptch1, and CyclinD1 and widespread expression of
granule precursor markers, such as Zic1 and Atoh1. Low
GNAS levels due to inactivating mutations define a subset
of SHH-MBs with an aggressive phenotype and are sug-
gested to be potential prognostic markers for treatment
stratification.86
Increased expression of Gli1 is a hallmark of elevated
SHH-signaling, however not all hedgehog-pathway
activation requires Gli1. The tumor microenvironment is
gaining increasing importance in SHH-pathway activation.
In a Ptch1-deficient mouse model, the intermediate fila-
ment protein Nestin is required for MB formation via
binding and inactivating Gli3.88 Nestin is expressed in
mature tissues in pathological situations when develop-
mental programs are recapitulated and is also a marker for
neural stem cells.89 Gli3 is a transcriptional repressor that
is proteolytically processed to its truncated form (Gli3R)
and acts predominantly as a negative regulator of SHH-
signaling. Progressively increasing Nestin levels during MB
development impair proteolytic processing of Gli3, abol-
ishing its inhibitory function. The Nestin-Gli3 interaction
augments SHH-signaling activation in the absence of
Ptch1, leading to tumorigenesis.88 Tumor-associated astro-
cytes (TAA) are multifunctional specialized glial cells
abundant in MBs.65 TAAs secret a functional SHH ligand
to the microenvironment that promotes cellular prolifera-
tion of MBs by inducing expression of Nestin. Targeting
TAAs or the expressed Shh ligand may be an alternative
treatment strategy against SHH-dependent MBs.65
In summary, despite the large number of murine mod-
els approximating human SHHs, the field lacks adequate
representation of the full spectrum of the disease. Infant
and adult SHH-MBs represent distinct subtypes with dif-
ferent gene expression patterns, genetic features, locations,
and clinical outcomes.12 Based on genomic and transcrip-
tional analyses, model systems utilizing Ptch1 and Smo
mutations match to human MBs well,90 but are suggested
to be more similar to adult tumors compared to infant
SHH-MBs.90 Mouse models of infant SHH-MBs are
needed for the development of more successful therapeu-
tic approaches for this age group.
Prospective Therapeutic
Opportunities
SMO inhibitors
Smoothened (SMO) regulates the suppression of SUFU91;
thus, potential SMO inhibitors could prevent SUFU acti-
vation and translocation of GLI proteins to the nucleus
(Fig. 3). Several small molecule inhibitors of SMO, such
as sonidegib (LDE-225) or vismodegib (GDC-0449), are
being investigated as potential agents in clinical trials,92,93
including ongoing trial NCT01878617, and demonstrate
particular efficacy in relapsed adult SHH-MBs.93,94
Approximately 80% of adult patients carry either PTCH1
or SMO mutations, rendering them to be likely respon-
ders to SMO inhibition. However, infants and children
frequently harbor mutations downstream of SMO and
thus may be resistant.26 GLI2 and MYCN amplification
or SUFU-driven SHH-signaling have consequences for
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targeted therapy. SMO inhibitors act upstream of these
genes; thus, GLI2- and MYCN-amplified tumors might be
refractory to agents targeting SMO.26,95,96 Resistance
against SMO inhibitors rapidly develops, and its mecha-
nisms are under intense research.97 De novo resistance is
linked to SMO mutations (such as D473H or E518), but
resistance can also develop downstream of SMO.94,96
Finally, SMO inhibitions have serious side effects in
pediatric patients because they inhibit bone and teeth
development: vismodegib-treated children developed
widespread growth plate fusions that persisted long after
therapy cessation.98 Drug-resistant SMO mutations high-
light the need for new therapies in SHH-MB. Itraconazole
has the ability to inhibit SMO activation, including some
SMO mutations that confer resistance to SMO inhibitors.
Arsenic trioxide inhibits GLI2 ciliary accumulation
(Fig. 3). These two drugs alone or in combination inhibit
in vitro cell growth and in vivo MB development in mice
bearing wild-type or SMO mutations and prolong the
survival of mice with SMO inhibitor-resistant medul-
loblastomas. Their combined administration seems to be
effective against all known SMO mutations.99
Statins
Cholesterol is an essential component of plasma mem-
branes, and its homeostasis is regulated by a tight net-
work of proteins. Enhanced expression of genes related to
cholesterol biosynthesis has been identified in SHH-
MBs.100 Statin treatment promotes differentiation and
inhibited proliferation in MB cells isolated from Ptch1+/
mice indicating that cholesterol is an essential component
of MB progression. Cholesterol and vismodegib bind
SMO at different binding sites, leading to synergistic
effects on tumor cells: inhibition of cholesterol biosynthe-
sis by statins alone or in combination with vismodegib
repressed in vivo SHH-MB proliferation and growths in
subcutaneous allograft tumors of Ptch1+/ mice.100 The
efficacy of statins depends on SHH-pathway mutations:
MBs with mutations in SmoM2 or downstream of SMO,
such as in SUFU or GLI2 are intrinsically resistant to
SMO- and cholesterol inhibitors. Potential combination
of statins with vismodegib may lead to reduced dosing of
the latter to prevent serious side effects in pediatric popu-
lations. Targeting cholesterol biosynthesis characterizes a
promising alternative treatment strategy for a subset of
SHH-MBs, nevertheless additional preclinical studies are
required prior to their clinical use.100
BET bromodomain inhibitors
Genomic amplifications of zinc finger transcription fac-
tors GLI2 and GLI1 of the SHH-signaling pathway have
been associated with more aggressive disease.95,101 BRD4
and other BET bromodomain proteins are critical regula-
tors of GLI1 and GLI2 transcription downstream of SMO
and SUFU. BET bromodomain inhibitors, such as JQ1,
target BRD4 and significantly decrease tumor cell viability
both in vitro and in vivo in genetically engineered mouse
models, even when genetic lesions predispose tumors to
resistance against SMO inhibitors.102
AURK or PLK inhibitors
A population of cells in the Ptch1 heterozygous mice
model of MB that express surface carbohydrate antigen
CD15/SSEA-1 augment tumor propagation following
transplantation. These cells display increased expression
of genes responsible for G2 and M phase regulation
throughout mitosis. CD15 is expressed in a subset of
human MBs associated with poor prognosis. Inhibition of
G2/M regulators, such as Aurora kinases (AURK) or
Polo-like kinases (PLK), reduces proliferation in vitro and
tumor growth in vivo, and thus may represent a novel
approach to treating CD15+SHH-MBs.103 In addition, a
class of Aurora kinase inhibitors may also disrupt the
native conformation of Aurora A and, as a consequence,
drive the proteolytic degradation of MYCN protein.104
cMET inhibitors
Aberrant MET-signaling is involved in metastasis develop-
ment in various solid tumors and is upregulated in pri-
mary SHH-MBs,50 plus phosphorylated MET kinase-
activity correlates with MB recurrence and poor sur-
vival.51 A MET inhibitor, foretinib, induced apoptosis
and inhibited migration and invasion in SHH-MB cell
lines, induced tumor regression, and prevented lep-
tomeningeal metastases in mouse xenografts.51
Targeting stem-like cells
Quiescent, therapy-resistant cells serve as a reservoir for
relapse. In a model of SHH-MB, cells expressing the
neural stem cell marker Sox2 comprised less than 5%
of the tumor but drove tumor growth after antimitotic
chemotherapy and SMO inhibition.68 Higher expression
of stem cell genes is associated with worse outcome in
numerous malignancies.105,106 Likewise, high SOX2
immunoreactivity is linked to worse survival in SHH
patients.68 Mithramycin, an agent against SOX2+ cells,
reduced the proliferation of human-derived primary
SHH-MB cell lines and growth of subcutaneous
allografts.68
Transducing NMyc in embryonic cerebellar cells induced
SHH-activated MB formation with the contribution of
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transcription factor SOX9.107 SOX9 regulates stem cell
properties, differentiation, proliferation, and survival and
is commonly elevated in WNT- and SHH-MBs, particu-
larly during early tumor initiation in a WNT/b-catenin-
dependent manner.108 FBW7, a protein participating in
substrate recognition, regulates posttranslational regula-
tion, particularly degradation of SOX9.109 FBW7 is fre-
quently mutated in SHH-MBs, and its expression is
downregulated across all MB subtypes. Lower levels of
FBW7 are associated with increased quantity of SOX9
protein, metastasis, and poor survival. SOX9 abundance
reduced the efficacy of cisplatin treatment both in vitro
and in vivo. Activation of PI3K/AKT/mTOR signaling is
associated with poor survival in adult SHH-MBs.26 Phar-
macological inhibition of PI3K/AKT/mTOR pathway
activity combined with cisplatin treatment stimulates
FBW7 expression, degrades SOX9 protein levels, and
increases apoptosis, providing a potential new opportu-
nity to treat recurrent, chemoresistant MB patients.110 In
an Nd2:SmoA1 transgenic mouse model of MB, tumor-
propagating CD15+ cells were regulated by Pten and
PI3K signaling and displayed sensitivity to pan-PI3K inhi-
bitor both in vivo and in vitro but remained resistant to
chemotherapy.111
The chemokine ligand CXCL12 and its receptor
CXCR4 are expressed in brain tumors (including medul-
loblastomas), and their expression is associated with poor
prognosis.112–114 CXCL12 and CXCR4 are potentially
important coactivators of SHH-signaling: SHH-CXCR4
coactivated tumors express higher levels of ATOH1 and
cyclin D1 and exhibit maximal tumor growth.114 Target-
ing Cxcr4 alone with the infusion of small molecule
antagonist AMD 3100 (plerixafor) inhibits growth of
intracranial MB xenografts by decreasing cellular prolifer-
ation and increasing apoptosis.115 Combined Shh and
Cxcr4 antagonism by vismodegib and plerixafor results in
a synergistic antitumoral effect in xenografts injected with
SmoA1-derived primary tumor cells by specifically target-
ing the MB stem-like cell pool, revealed by decreased
expression of stem cell markers Bmi1 and Sox2.116
Immunotherapy
Immunological differences within the tumor microenvi-
ronment across MB subtypes suggest different regulatory
mechanisms and determine possible immunotherapeutic
strategies. Increased expression of inflammation-related
genes and elevated infiltration of tumor-associated macro-
phages (TAM) were described in SHH-MBs compared to
Group3 and Group 4 tumors.117 Likewise, increased fre-
quencies of CD4+ and CD8+ T cells, myeloid cells, and
dendritic cells were identified in Ptch1+/ SHH-MB-bear-
ing mice compared to another model of MYC-amplified
MBs, characterized by a higher proportion of CD8+ PD-
1+ double positive T cells.118 The higher percentage of
infiltrating myeloid-derived suppressor cells and TAMs in
SHH-MBs suggests an immunologically suppressive
tumor microenvironment. Accordingly, treatment with
either anti-CTLA-4 alone, anti-PD-1 alone, or in combi-
nation was not effective in Ptch1+/ SHH-MB-bearing
mice but showed survival benefits in MYC-amplified
tumor bearing animals.118
There is a pronounced urgency for alternative thera-
peutic modalities in pediatric brain malignancies. Identifi-
cation of differentially expressed cell surface markers
between tumor and normal cells may lead to novel
immunotherapeutic strategies. The tumor-associated anti-
gen, PRAME, is detected in the majority of MB samples
but not in normal tissue, and high PRAME expression
correlates with worse survival.119 Genetically modified T
cells directed toward the PRAME antigen both in vitro
and in vivo were effective against multiple HLA-
A*02+ MB cell lines, including DAOY cells. Adoptive
immunotherapy targeting PRAME represents a promising
innovative approach for patients with HLA-A*02+
MBs.119 Comparing high-risk neuroblastomas and normal
tissues identified differential expression of tumor-specific
cell surface molecule, Glypican 2 (GPC2), an extracellular
proteoglycan signaling coreceptor, required for cellular
proliferation. A GPC2-directed antibody-drug conjugate,
D3-GPC2-PBD was effective against neuroblastoma cells
in vitro in an antigen- and concentration-dependent
manner, and in vivo in murine PDX models.120 GPC2 is
also highly expressed both in primary and metastatic
MBs, and similarly to neuroblastomas, MBs express the
GPC2 transcript. GPC2 expression is highest among
Group 4 MBs, but the relatively high expression across
SHH- and Group 3 MBs suggests its potential relevance
in other subtypes as well.120
Conclusions
An enormous amount of data on the genetic background
of SHH-activated MBs have accumulated in the past dec-
ade. While subgroup affiliation still does not provide reli-
able prediction of therapy response, emerging models
offer more layered patient stratification. A more collective
approach could accelerate translation of new insights into
clinical practice. Collaborative efforts with improved
communication, material, and data sharing could permit
the development of better tailored preclinical models for
basic biology studies and therapeutic development, and
facilitate the integration of multilayer (genomic, epige-
netic, proteomic, and metabolomic) molecular data to
uncover novel disease biomarkers. Rational clinical trial
design with the incorporation of available molecular
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understanding, focusing especially on high-risk patients
are inevitable and may bring the much-sought-after
breakthrough in the stagnant survival rates of the past
decades.
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